Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
2.945
+0.065 (2.26%)
At close: Sep 12, 2025, 4:00 PM EDT
2.940
-0.005 (-0.17%)
After-hours: Sep 12, 2025, 4:00 PM EDT
Evaxion Revenue
Evaxion had revenue of $37.00K in the quarter ending June 30, 2025, a decrease of -75.97%. This brings the company's revenue in the last twelve months to $3.18M, up 1,042.45% year-over-year. In the year 2024, Evaxion had annual revenue of $3.34M with 4,480.82% growth.
Revenue (ttm)
$3.18M
Revenue Growth
+1,042.45%
P/S Ratio
2.50
Revenue / Employee
$69,043
Employees
46
Market Cap
18.60M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.34M | 3.27M | 4,480.82% |
Dec 31, 2023 | 73.00K | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
EVAX News
- 26 days ago - Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025 - GlobeNewsWire
- 7 weeks ago - Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025 - GlobeNewsWire
- 2 months ago - Evaxion finalizes agreement with EIB to convert debt into equity - GlobeNewsWire
- 2 months ago - Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio - GlobeNewsWire
- 2 months ago - Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus - GlobeNewsWire
- 3 months ago - Evaxion receives grant funding to design new polio vaccine - GlobeNewsWire
- 3 months ago - Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha